| Autor: |
Dhuli, K., Micheletti, C., Medori, M. C., Maltese, P. E., Tanzi, B., Tezzele, S., Mareso, C., Generali, D., Donofrio, C. A., Cominetti, M., Fioravanti, A., Riccio, L., Beccari, T., Ceccarini, M. R., Stuppia, L., Gatta, V., Cristoni, S., Cecchin, S., Marceddu, G., Bertelli, M. |
| Předmět: |
|
| Zdroj: |
Clinica Terapeutica; 2023 Supplement, Vol. 174, p46-54, 9p |
| Abstrakt: |
In the last decade, renal carcinoma has become more prevalent in European and North American regions. Kidney tumors are usually categorized based on histological features, with renal cell carcinoma being the most common subtype in adults. Despite conventional diagnostic and therapeutic strategies, a rise in cancer incidence and recurrence necessitates a fresh approach to diagnosing and treating kidney cancer. This review focuses on novel multi-omics approaches, such as genomics, transcriptomics, proteomics, metabolomics, and microbiomics, to better understand the molecular and clinical features of renal cell carcinoma. Studies integrating omics sciences have shown early promise in enhancing prognostic and therapeutic outcomes for various kidney cancer subtypes and providing insight into fundamental pathophysiological mechanisms occurring at different molecular levels. This review highlights the importance of utilizing omics sciences as a revolutionary concept in diagnostics and therapeutics and the clinical implications of renal cell carcinoma. Finally, the review presents the most recent findings from large-scale multi-omics studies on renal cell carcinoma and its associations with patient subtyping and drug development. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
